USANA Health Sciences delivered positive second quarter results with an 11% year-over-year consolidated net sales growth, reaching $236 million. However, net earnings decreased by 7% to $9.7 million, and diluted EPS fell by 4% to $0.52. The company's direct-to-consumer business, Hiya, continued its strong growth, while the direct selling business is undergoing a comprehensive commercial strategy rollout.
Net sales increased by 11% year-over-year to $236 million, driven by strong performance in the Hiya direct-to-consumer business.
Net earnings decreased by 7% to $9.7 million, and diluted EPS was $0.52, down from $0.54 in the prior year.
Adjusted diluted EPS saw a significant increase of 36% to $0.74, reflecting the exclusion of acquisition-related costs.
The company reiterated its full-year 2025 outlook, anticipating continued growth in net sales and profitability.
USANA Health Sciences reiterated its fiscal year 2025 outlook, expecting consolidated net sales between $920 million and $1.0 billion, and diluted EPS between $1.50 and $2.20. The company anticipates continued growth in both its direct selling and Hiya businesses, with a focus on strategic initiatives and managing promotional costs.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance